Incyte (INCY) Tops Q3 EPS by 33c; Jakafi Sales Up 63%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Goldman Sachs Upgrades Incyte (INCY) to Neutral
October 31, 2014 7:20 AM EDTGoldman Sachs upgraded Incyte (NASDAQ: INCY) from Sell to Neutral with a price target of $62.00 (from $32.00).
Analyst Navdeep Singh said, "Our Sell thesis was based on our more cautious view on Jakafis launch for myelofibrosis (MF) given safety and competition,... More



